Delivery Order SPE2DB20D3104-SPE2DB25FV6F3

Award Date 4/3/25
Potential Completion Date 4/4/25
Potential Value $17K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,087.08 firm fixed-price delivery order is for the supply of 4,563,680,292 units of 8 mg Ondansetron HCL tablets. The contract has an ultimate completion date of February 16, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This federal contract award from the Defense Logistics Agency (DLA) was issued to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,204.32 firm fixed-price delivery order is for the supply of 4 mg ondansetron orally disintegrating tablets. The contract has an ultimate completion date of January 16, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is a Delivery Order with a Firm Fixed Price valued at $1,858.09 for the supply of 4 mg Ondansetron HCL tablets. The contract has an ultimate completion date of October 27, 2023. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,137.76 Firm Fixed Price Delivery Order covers the supply of 4 mg Ondansetron HCL tablets in 500-count bottles. The contract has an ultimate completion date of January 14, 2025 and was awarded on January 13, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award from the Defense Logistics Agency (DLA) was issued to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,011.88 firm-fixed-price delivery order is for the supply of 4 mg Ondansetron HCL tablets. The contract has an ultimate completion date of July 22, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,266.42, is for the delivery of Ondansetron ODT 4 mg tablets. The contract is a Firm Fixed Price Delivery Order with a completion date of March 6, 2025. AmerisourceBergen has previously been awarded a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,893.58, is a delivery order for the supply of Ondansetron ODT 4 mg tablets. The contract has an ultimate completion date of November 22, 2024 and is a firm fixed-price contract. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $28,999.00, is a Delivery Order for the supply of 4,566,304,145 units of Ondansetron HCL 4 mg Tablets. This Firm Fixed Price contract has an ultimate completion date of November 4, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was granted by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order valued at $4,733.59 for the supply of 4,566,262,385 units of Ondansetron HCL 8 mg tablets. The contract has an ultimate completion date of October 30, 2024 and is a firm fixed-price arrangement. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,695.23, is for the delivery of Ondansetron ODT 4 mg tablets. This is a firm-fixed-price delivery order contract with a completion date of January 23, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
  • SPE2DB20D3104
    Indefinite Delivery Contract
  • SPE2DB20D3104-SPE2DB25FV6F3
    Delivery Order

This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order worth $16,741.02 for the supply of 4 mg Ondansetron HCL tablets. The contract has an ultimate completion date of April 4, 2025 and is a Firm Fixed Price type. AmerisourceBergen has a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999 through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This contract award is not designated as a set-aside and represents open competition.

Generated 7/3/25, 3:05 PM